Atomoxetine is a highly potent inhibitor of presynaptic norepinephrine transporters. Atomoxetine has minimal affinity for other noradrenergic receptors or other receptors or transporters of neurotransmitters.
Does not apply sustanon side effects to psychostimulants and is not derived from amphetamine. In clinical trials, the abolition of the drug were observed amplification of symptoms or any adverse events related to withdrawal syndrome.
Suction Atomoxetine is rapidly and almost completely absorbed after oral administration, reaching the maximum concentration in plasma after about 1 – 2 hours. Atomoxetine is assigned regardless of the meal or during a meal.
Distribution. Atomoxetine is well distributed in the body. Atomoxetine has a high affinity to plasma proteins, mainly albumin.
Metabolism. Atomoxetine is primarily passes through biotransformation cycle enzyme cytochrome. The main image is oxidized metabolite 4-gidroksiatomoksetin glyukuroniruetsya quickly. 4 by the action gidroksiatomoksetin equivalent atomoxetine but circulates in plasma at much lower concentrations.
Although 4-gidroksiatomoksetin primarily formed using for people with pooractivity gidroksiatomoksetin 4 can be formed by some other cytochrome enzymes, but more slowly.
Atomoxetine does not inhibit and increases the cycle.
The average half-life of atomoxetine after oral administration is 3.6 hours in patients with severe metabolic and 21 hours in patients with reduced metabolism. Atomoxetine is mainly excreted in the urine.
Attention Deficit Hyperactivity in children 6 years of age and older, adolescents and adults.
- Hypersensitivity to the drug
- Concomitant use with monoamine oxidase inhibitors
- Angle-closure glaucoma
- Severe heart disease
In patients sustanon side effects with hypertension, tachycardia, cardiovascular diseases, severe physical congestion, while taking psychostimulants, sudden cardiac death in the family history, cerebrovascular, convulsive seizures in history, as well as conditions that may result in hypotension (see . “Special instructions” section).
Use during pregnancy and breast-feeding
Because of insufficient experience with atomoxetine during pregnancy, the drug should be used during pregnancy only if the potential benefit to the patient is much higher than the potential risk to the fetus.
It is not known if atomoxetine is excreted in breast milk. Caution should be exercised when administering the drug lactating women.
Dosage and administration
For oral administration.
Preparation Strattera ® may be administered in a single daily dose in the morning. In case of adverse events while taking the drug in the form of a single daily dose may be recommended for patients taking the drug twice a day, dividing the dose in the morning and welcome reception in the late afternoon or early evening.
Children and adolescents weighing less than 70 kg. The recommended initial daily dose is about 0.5 mg / kg and increased to a therapeutic daily dose of approximately 1.2 mg / kg, not earlier than 3 days. If there is no improvement in the condition of the patient, the total daily dosage may be increased up to a sustanon side effects maximum dose of 1.8 mg / kg, no sooner than 2-4 weeks after starting treatment.
The recommended maintenance dose is approximately 1.2 mg / kg / day. The recommended maximum daily dose is 1.8 mg / kg or 120 mg.
In children and adolescents with a body weight up to 70 kg safety of single and total daily doses greater than 1.8 mg / kg have not been systematically evaluated.